Market closedNon-fractional
RAPT Therapeutics/RAPT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About RAPT Therapeutics
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Ticker
RAPT
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
South San Francisco, United States
Employees
126
Website
www.rapt.com
RAPT Metrics
BasicAdvanced
$109M
Market cap
-
P/E ratio
-$3.08
EPS
0.52
Beta
-
Dividend rate
Price and volume
Market cap
$109M
Beta
0.52
Financial strength
Current ratio
7.009
Quick ratio
6.688
Long term debt to equity
2.916
Total debt to equity
4.833
Management effectiveness
Return on assets (TTM)
-39.60%
Return on equity (TTM)
-67.21%
Valuation
Price to book
0.83
Price to tangible book (TTM)
0.83
Price to free cash flow (TTM)
-1.131
Growth
Earnings per share change (TTM)
15.30%
3-year earnings per share growth (CAGR)
10.28%
What the Analysts think about RAPT
Analyst Ratings
Majority rating from 11 analysts.
RAPT Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$31M
-0.97%
Profit margin
0.00%
NaN%
RAPT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.66
-$0.82
-$0.80
-$0.79
-
Expected
-$0.78
-$0.75
-$0.86
-$0.81
-$0.71
Surprise
-15.57%
8.86%
-6.85%
-2.26%
-
RAPT News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RAPT Therapeutics stock?
RAPT Therapeutics (RAPT) has a market cap of $109M as of July 27, 2024.
What is the P/E ratio for RAPT Therapeutics stock?
The price to earnings (P/E) ratio for RAPT Therapeutics (RAPT) stock is 0 as of July 27, 2024.
Does RAPT Therapeutics stock pay dividends?
No, RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next RAPT Therapeutics dividend payment date?
RAPT Therapeutics (RAPT) stock does not pay dividends to its shareholders.
What is the beta indicator for RAPT Therapeutics?
RAPT Therapeutics (RAPT) has a beta rating of 0.52. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell RAPT Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.